---
title: "Vabysmo (faricimab-svoa), all indications: Safety questions"
description: "Safety questions on Vabysmo (faricimab-svoa) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Warnings, and Monitoring. Questions: What are the most common side effects of Vabysmo? Can patients develop antibodies to Vabysmo? Who should not receive Vabysmo (contraindications)? Can Vabysmo cause allergic reactions? 8 further questions follow. 12 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/vabysmo/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa), all indications: Safety questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)  
Indication pages: [Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration)

## Side effects

<a id="vabysmo-side-effects"></a>

### What are the most common side effects of Vabysmo?

> “The most common adverse reactions (≥ 5%) reported in patients receiving 
> VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).”

Source: [VABYSMO: Prescribing information, page 1, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=1)

> “Less common adverse reactions reported in < 1% of the patients treated with VABYSMO were  
> corneal abrasion, eye pruritus, ocular hyperemia, blurred vision, sensation of foreign body, 
> endophthalmitis, conjunctival hyperaemia, visual acuity reduced, visual acuity reduced 
> transiently, vitreous hemorrhage, retinal tear and rhegmatogenous retinal detachment.”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

> “Table 1: Common Adverse Reactions (≥ 1%)”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

> “Adverse Reactions 
>
> VABYSMO 
> Active Control (aflibercept)  
> AMD 
> N=664 
> DME 
> N=1,262 
> RVO 
> N=641 
> AMD 
> N=662 
> DME 
> N=625 
> RVO 
> N=635 
> Cataract 
> 3% 
> 15% 
> < 1% 
> 2% 
> 12% 
> 1% 
> Conjunctival hemorrhage 
> 7% 
> 8% 
> 3% 
> 8% 
> 7% 
> 4%”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

Note: The 15% and 8% figures in the first passage match the DME columns of Table 1. In the wet AMD trials (TENAYA and LUCERNE) the Table 1 rates were 3% for cataract and 7% for conjunctival hemorrhage. Table 1 columns are VABYSMO in AMD (N=664), DME (N=1,262), and RVO (N=641), then aflibercept in AMD (N=662), DME (N=625), and RVO (N=635), in that order; the AMD columns are the wet AMD trials (TENAYA and LUCERNE).

<a id="vabysmo-antibodies"></a>

### Can patients develop antibodies to Vabysmo?

> “There is a potential for an immune response in patients treated with VABYSMO. In the nAMD, 
> DME, and RVO studies, the pre-treatment incidence of anti-faricimab antibodies was 
> approximately 0.8 to 1.8%. After initiation of dosing, the incidence of anti-faricimab antibodies 
> was approximately 8% to 10.4% in patients treated with VABYSMO across studies. As with all 
> therapeutic proteins, there is a potential for immunogenicity with VABYSMO.”

Source: [VABYSMO: Prescribing information, page 15, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=15)

## Warnings

<a id="vabysmo-contraindications"></a>

### Who should not receive Vabysmo (contraindications)?

> “VABYSMO is contraindicated in patients with ocular or periocular infections. 
>
> 4.2 
> Active Intraocular Inflammation 
> VABYSMO is contraindicated in patients with active intraocular inflammation. 
>
> 4.3 
> Hypersensitivity 
> VABYSMO is contraindicated in patients with known hypersensitivity to faricimab or any of the 
> excipients in VABYSMO. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, 
> erythema, or severe intraocular inflammation.”

Source: [VABYSMO: Prescribing information, page 10, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=10)

<a id="vabysmo-allergic-reactions"></a>

### Can Vabysmo cause allergic reactions?

> “VABYSMO is contraindicated in patients with known hypersensitivity to faricimab or any of the 
> excipients in VABYSMO. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, 
> erythema, or severe intraocular inflammation.”

Source: [VABYSMO: Prescribing information, page 10, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=10)

<a id="vabysmo-endophthalmitis-retinal-detachment"></a>

### Can Vabysmo cause eye infection (endophthalmitis) or retinal detachment?

> “Intravitreal injections, including Vabysmo, have been associated with endophthalmitis and 
> retinal detachments [see Adverse Reactions (6.1)]. Proper aseptic injection techniques must 
> always be used when administering VABYSMO. Patients should be instructed to report any 
> signs or symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit 
> prompt and appropriate management [see Dosage and Administration (2.6) and Patient 
> Counseling Information (17)].”

Source: [VABYSMO: Prescribing information, page 10, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=10)

<a id="vabysmo-eye-pressure"></a>

### Does Vabysmo raise eye pressure (IOP)?

> “Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of intravitreal injection, including with VABYSMO. IOP and the perfusion of the optic nerve head should be monitored and managed appropriately.”

Source: [VABYSMO: Important Safety Information, captured 2026-11-13](https://www.vabysmo-hcp.com/important-safety-information.html#:~:text=Transient%20increases%20in%20intraocular%20pressure,be%20monitored%20and%20managed%20appropriately.)

<a id="vabysmo-retinal-vasculitis"></a>

### Can Vabysmo cause retinal vasculitis or retinal vascular occlusion?

> “Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular 
> inflammation, have been reported with the use of VABYSMO [see Adverse Reactions (6.2)].  
> Discontinue treatment with VABYSMO in patients who develop these events. Patients should be 
> instructed to report any change in vision without delay.”

Source: [VABYSMO: Prescribing information, page 11, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=11)

> “Eye disorders: retinal vasculitis with or without retinal vascular occlusion.”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

> “Retinal vasculitis with or without occlusion, typically in the presence of intraocular inflammation, have been reported with the use of VABYSMO in the postmarketing setting.<sup>1</sup>”

Source: [VABYSMO: Safety Profile, captured 2026-11-13](https://www.vabysmo-hcp.com/safety-profile.html#:~:text=Retinal%20vasculitis%20with%20or%20without,of%20VABYSMO%20in%20the%20postmarketing)

> “No reported cases of retinal vasculitis with or without occlusion in VABYSMO's 6 pivotal clinical trials.<sup>1,2¶</sup>”

Source: [VABYSMO: Safety Profile, captured 2026-11-13](https://www.vabysmo-hcp.com/safety-profile.html#:~:text=No%20reported%20cases%20of%20retinal,in%20VABYSMO%27s%206%20pivotal%20clinical)

> “After 1 year in nAMD, 2 years in DME, and 6 months in RVO.”

Source: [VABYSMO: Safety Profile, captured 2026-11-13](https://www.vabysmo-hcp.com/safety-profile.html#:~:text=After%201%20year%20in%20nAMD%2C,and%206%20months%20in%20RVO.)

Note: The last passage is the footnote (¶) to the statement before it.

## Monitoring

<a id="vabysmo-monitoring-after-injection"></a>

### What monitoring is needed after a Vabysmo injection?

> “Immediately following the intravitreal injection, patients should be monitored for elevation in 
> intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic 
> nerve head or tonometry. If required, a sterile paracentesis needle should be available.”

Source: [VABYSMO: Prescribing information, page 10, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=10)

> “Following intravitreal injection, patients should be instructed to report any symptoms 
> suggestive of endophthalmitis or retinal detachment (e.g., vision loss, eye pain, redness of the 
> eye, photophobia, blurring of vision) without delay [see Patient Counseling Information 
> (17)].”

Source: [VABYSMO: Prescribing information, page 10, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=10)

## Safety

<a id="vabysmo-symptoms-to-report"></a>

### What symptoms should patients report after a Vabysmo injection?

> “Advise patients that in the days following VABYSMO administration, patients are at risk of 
> developing endophthalmitis, retinal detachment, intraocular inflammation and retinal vasculitis 
> with or without retinal vascular occlusion. If the eye becomes red, sensitive to light, painful, or 
> develops a change in vision, advise the patient to seek immediate care from an ophthalmologist 
> [see Warnings and Precautions (5)].”

Source: [VABYSMO: Prescribing information, page 24, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=24)

<a id="vabysmo-driving"></a>

### Can patients drive after a Vabysmo injection?

> “Patients may experience temporary visual disturbances after an intravitreal injection with 
> VABYSMO and the associated eye examinations [see Adverse Reactions (6)]. Advise patients 
> not to drive or use machinery until visual function has recovered sufficiently.”

Source: [VABYSMO: Prescribing information, page 24, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=24)

<a id="vabysmo-cancer-data"></a>

### Has Vabysmo been tested for cancer risk (carcinogenicity)?

> “No carcinogenicity or mutagenicity data are available for VABYSMO injection in animals or 
> humans.”

Source: [VABYSMO: Prescribing information, page 15, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=15)

<a id="vabysmo-report-side-effects"></a>

### How do I report Vabysmo side effects?

> “To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 
> 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.”

Source: [VABYSMO: Prescribing information, page 1, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=1)

## Related pages
- [Medical information: Vabysmo (faricimab-svoa): All indications](https://www.evicenter.com/medical-information/vabysmo)
- [Indication](https://www.evicenter.com/medical-information/vabysmo/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vabysmo/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/vabysmo/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/vabysmo/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vabysmo/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vabysmo/access-and-coverage)
